aTYR PHARMA (ATYR) Cash from Financing Activities (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Cash from Financing Activities data on file, last reported at -$142000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 100.76% year-over-year to -$142000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.2 million (down 6.94% YoY) and the FY2025 annual result came in at $66.0 million, up 65.59% from the prior year.
• Cash from Financing Activities declined to -$142000.0 in Q1 2026, from -$131000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $49.5 million in Q1 2023 to a low of -$142000.0 in Q1 2026.
• A 5-year average of $10.4 million and a median of $6.0 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities sank 103.91% — and 2025, when it soared 28306.67%.
• Tracing ATYR's Cash from Financing Activities over 5 years: stood at $918000.0 in 2022, then jumped by 557.3% to $6.0 million in 2023, then soared by 212.21% to $18.8 million in 2024, then plunged by 100.7% to -$131000.0 in 2025, then declined by 8.4% to -$142000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$142000.0 (Q1 2026), -$131000.0 (Q4 2025), and $29.6 million (Q3 2025), per Business Quant data.